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Abstract
Background: We have used commercially available cDNA arrays to identify EphB4 as a gene that
is up-regulated in colon cancer tissue when compared with matched normal tissue from the same
patient.
Results: Quantitative RT-PCR analysis of the expression of the EphB4 gene has shown that its
expression is increased in 82% of tumour samples when compared with the matched normal tissue
from the same patient. Using immunohistochemistry and Western analysis techniques with an
EphB4-specific antibody, we also show that this receptor is expressed in the epithelial cells of the
tumour tissue and either not at all, or in only low levels, in the normal tissue.
Conclusion: The results presented here supports the emerging idea that Eph receptors play a role
in tumour formation and suggests that further elucidation of this signalling pathway may identify
useful targets for cancer treatment therapies.
Background
Colorectal cancer (CRC), arising from epithelial cells lin-
ing the large intestine, is the most commonly occurring
internal cancer among Australians. Of all forms of cancer,
it has the second highest mortality rate for both men and
women, after lung cancer and breast cancer, respectively.
Recently in Australia, the screening of all individuals over
the age of 50 years for colon cancer has been proposed but
although several genes may have good prognostic poten-
tial, a reliable genetic test for this disease has not yet been
developed [1–3]. Further to this problem, up to 30% of
patients undergoing supposed curative resection for early
stage disease will relapse and die within 5 years, suggest-
ing that metastatic spread is already underway in these pa-
tients.
In an effort to identify new markers for colon cancer, we
have screened cDNA arrays to identify genes that show
marked up-regulation in colon tumour cells when com-
pared with matched normal mucosa. EphB4, a member of
the largest known family of receptor protein tyrosine ki-
nases, was identified as a gene that showed consistent up-
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regulation in the patient tumour samples, when com-
pared with the normal tissue, by array analysis. Eph recep-
tors are involved in many cellular processes including
neural development, angiogenesis and vascular network
assembly [4–9]. They are large multi-domain membrane-
anchored proteins consisting of six different regions [10]
including a globular domain and a SAM domain, for
which crystal structures have been determined [11,12]. As
a result of Eph-ephrin binding, the receptor autophospho-
rylates allowing interaction with a variety of different pro-
teins that regulate cytoskeletal organisation and cell
motility [13,14]. The role of EphB4 and other Eph recep-
tor family members in cancer has not yet been defined, al-
though up-regulation of the expression of several of these
has been demonstrated in tumours and cells lines from
gastric tissues, prostate, breast, endometrium, and lung
[15–23]. Here we present the results of experiments de-
signed to further investigate the expression of this gene
and to clarify its biological relevance to the progression of
human colorectal adenocarcinomas. These results suggest
that pathways involving Eph-ephrin signalling may be im-
portant in the progression of colon cancer and that thera-




Clontech Atlas expression arrays were differentially
screened with cDNA probes made using RNA extracted
from 2 pairs of matched tumour and normal mucosa sam-
ples (2 different patients) to identify genes that were up-
regulated in tumour tissue. Images were visualised using a
phosphorimager. Comparison of two different tumour/
normal pairs identified EphB4 as consistently up-regulat-
ed in the tumour samples when compared to the matched
normal tissue (ranked as the gene with the greatest differ-
ence in one patient and third greatest difference in the
other using a proprietary algorithm developed by us) and
it was therefore chosen for further analysis.
Identification of a pseudogene sequence corresponding to 
EphB4 gene
Primers EphB4F1 and EphB4R1 were designed to amplify
a 466 bp product corresponding to bases 1377 – 1843 of
the EphB4 cDNA sequence. Comparison with the EphB4
genomic sequence (Accession AY056047), shows that
these primers span 4 introns and approximately 6 kb, al-
lowing distinction of the cDNA and genomic products (a
genomic product will not be synthesised under the condi-
tions used in the RT-PCR analysis). However, when these
primers were used in a PCR reaction using genomic DNA
from six different patients as the template, bands of a sim-
ilar size to the cDNA product were amplified (result not
shown). The product from one of these patients was se-
quenced fully in both directions and it did not differ sig-
nificantly from the EphB4 cDNA sequence. Because this
suggested the presence of a pseudogene, further primers
(EphB4F3 and EphB4R3) corresponding to bases 1819 –
3005 of the EphB4 cDNA sequence were designed to am-
plify a larger cDNA product of 1187 bp. As these did not
amplify a product from the genomic template (primers
span >10 kb), they were used for the RT-PCR analysis de-
scribed later.
Expression of EphB4 in colon cancer cell lines
The expression of EphB4 was assessed for its suitability as
a tumour specific marker using RT-PCR. RNA was extract-
ed from ten colon cancer cell lines, reverse transcribed
into cDNA then PCR-amplified using primers specific for
the different genes. A primer set specific to CK19, a well
characterised marker of colon epithelial cells [25–27], was
used as a control for confirming integrity of the RT reac-
tion. Transcripts corresponding to EphB4 and CK19 were
amplified from all of the 10 cell lines (Figure 1).
Expression of EphB4 in primary colon tumours
Total RNA was extracted from 62 tumours and matched
normal mucosal tissue taken from 60 patients (1 patient
had three separate tumours) undergoing resection for pri-
mary colon cancer. Total RNA from liver metastases con-
sistent with colorectal primary tumours, and normal liver
samples from five of the CRC patients was also isolated.
RNA was reverse transcribed and PCR amplified to com-
pare levels of expression of each of the selected genes in
the tumour and the matched normal mucosa. Semi-quan-
titative results were obtained by amplifying CK19 tran-
scripts at the same number of cycles (Figure 2). As the
same amount of RNA was transcribed for each sample at
the same time, variation in the amount of CK19 amplified
product in the cDNA samples may reflect normal varia-
tion in expression of these genes in the tumour and
matched normal tissue. The amplification of this marker
also demonstrates the integrity of the cDNA used for the
EphB4 analysis. EphB4 showed increased expression in
30/38 (79%) of tumours analysed (as compared with the
normal mucosa). As expected, from analysis of data in the
EST databases, we did find that the EphB4 gene was ex-
pressed in normal liver, but it was also expressed to a sim-
ilar level in the liver metastasis from patient 5 (consistent
with colon origin). Analysis of other liver metastases will
determine whether the apparent decrease in expression in
the secondary tumour deposit when compared to the pri-
mary tumour is a consistent observation.
To quantify the expression of EphB4 in the tumour and
normal samples for direct comparison of gene expression
we used relative RT-PCR (Ambion). The amount of EphB4
transcript was quantified by concurrently amplifying a
489 bp fragment of the 18S ribosomal unit as an internal
control in a multiplexed reaction (Figure 3). Using a gelBMC Molecular Biology 2001, 2:15 http://www.biomedcentral.com/1471-2199/2/15
Page 3 of 9
(page number not for citation purposes)
documentation system, the expression of the EphB4 gene
was calculated relative to the level of 18S rRNA amplified
from the same sample in the same PCR tube, and ex-
pressed as a ratio. This allowed direct comparison of the
tumour and normal tissue paired samples. Quantification
of both the 18S product and the EphB4 product showed
that EphB4 was up-regulated greater than 1.5 times in 51/
62 (82%) of tumour samples when compared with the
normal mucosa and greater that 2 times in 39/62 (63%).
An ANOVA test of the results of three identical experi-
ments using seven paired tumour/normal samples
showed there was no statistical difference between exper-
iments. A paired, matched Student's T-test showed that
the difference between the levels of EphB4 expression in
the tumour tissues and the levels of EphB4 expression in
the normal tissues was significant (P < 0.0001).
Western analysis confirms that EphB4 protein is increased 
in colon tumours and low in matched normal mucosa
To determine if the increased expression of the EphB4
gene corresponded to an increase in the EphB4 protein we
performed western analysis of colon and matched normal
tissues using an EphB4-specific polyclonal antibody. The
predicted size of wildtype EphB4 protein has been esti-
mated by Bennet et al., (1994) to be 120 kD and in our ex-
periment a band of this size was present in protein extracts
from the tumour samples but low or absent in extracts
from the normal mucosa (Figure 4) [28]. This confirms
that the increased expression in the tumour tissues does
correspond to an increase amount of the protein itself.
Additional signals corresponding to proteins of lower mo-
lecular weight were also visible specifically in the tumour
samples. It is unknown at this time whether these are
EphB4-specific cleavage products or not and this will be
the subject of future investigation. Further samples will be
need to be tested to determine if there is any association
between the stage of tumour development and amount of
protein present.
Immunohistochemical analysis of EphB4 expression in co-
lon tumour and matched normal mucosa
To localise the expression of EphB4 in normal and tu-
mour tissue, we performed immunohistochemistry on 6
matched samples using an EphB4 specific antibody. The
results for three patient sample sets are presented in Figure
5. The epithelial layer in the normal tissue and a well dif-
ferentiated and a moderately-well differentiated tumour
can be clearly distinguished by the single row of regular
nuclei (stained blue with Harris Haematoxylin) lining the
crypts. The most intense staining was localised to the tu-
Figure 1
Expression of EphB4 and CK19 in ten colon cancer cell lines -LIM2099, LIM2412, LIM1863, SW48, LIM1899, LIM1215, SW480,
HT29, LIM2405 and SW620. Sizes of the amplified products are indicated on the right. RT-ve – RT negative control, PCR -ve –
PCR negative control, M – pUC19 HpaII marker.BMC Molecular Biology 2001, 2:15 http://www.biomedcentral.com/1471-2199/2/15
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mour epithelial cells as shown by the brown staining.
Both the absorptive, surface epithelial cells and crypt mu-
cus-secreting cells of the tumour tissue showed strong
staining at the cell membranes with comparable intensity
at both the apical and basal surfaces. The poorly differen-
tiated tumour appears to be a mass of EphB4-expressing
cells. There was no obvious staining of endothelial cells of
blood vessels, confirmed by immunohistochemical anal-
ysis of human umbilical vein endothelial cells grown on
slides (data not shown) and only weak diffuse staining in
Figure 2
Semiquantitative analysis of EphB4 gene expression in five tumour (T) and normal (N) pairs, one of which includes a liver
metastasis consistent with the colorectal primary from this patient (LM) and a normal liver sample (NL), by comparison with
CK19 expression. Sizes of the amplified products are indicated on the right. C1 – colon cancer cell line LIM2405, C2 – colon
cancer cell line SW480, RT- RT negative control, P – PCR negative control, M -pUC19 HpaII marker.
Figure 3
Relative RT-PCR comparing expression of EphB4 (1187 bp) and internal 18S rRNA (489 bp) in the same five tumour (T)/ nor-
mal (N) pairs shown in Fig 4. C1 – colon cancer cell line LIM2405, C2 – colon cancer cell line SW480, RT- RT negative control,
P – PCR negative control, M – pUC19 HpaII marker.BMC Molecular Biology 2001, 2:15 http://www.biomedcentral.com/1471-2199/2/15
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the normal tissue. There was no staining with the second-
ary antibody alone (results not shown).
Discussion
Currently, tumour-specific gene markers for colon cancer
are not available and further characterisation of gene ex-
pression in tumour cells is required. The development of
cDNA array technology has enabled the expression analy-
sis of a large number of genes using differential screening
techniques. We have used cDNA arrays (Clontech) to an-
alyse the expression pattern of 588 genes, chosen for their
defined roles in processes such as oncogenesis, prolifera-
tion and apoptosis. A combination of data from two dif-
ferent patient samples identified EphB4 as a potential
candidate marker and relative RT-PCR analysis and im-
munohistochemistry has been used to demonstrate that
up-regulation of expression of this gene in tumour epithe-
lial cells is a common feature of colon tumours.
Up-regulation of the expression of several members of the
Eph family of receptor tyrosine kinases has been associat-
ed with cancers from breast, lung and gastric tissues which
implies an important function for these proteins in the de-
velopment and/or function of the tumour cells [15–23]
Protein tyrosine kinases collectively make up the largest
family of oncogenes. Since they function in signal path-
ways that control cell shape, proliferation, differentiation
and migration, there would seem to be many potential
ways in which their dysregulation could promote tumori-
genesis (reviewed in [29] and [30]).
It is possible that Eph receptors and ephrins have parallel
or co-operative roles in cell adhesion systems and in re-
stricting cell intermingling during development. Studies
of EphR signalling during embryonic development show
that these receptor molecules are involved in processes
which alter the cell cytoskeleton and may regulate the
function of cell adhesion molecules causing de-adhesion
of cells at boundaries [6]. Alternatively or in addition, ac-
tivation may trigger cell repulsion responses involving the
localised collapse of the actin cytoskeleton. Zisch et al
(2000) have used a panel of EphB2 mutants to show that
receptor kinase activity is required for changes in cell-ma-
trix and cell-cell adhesion and cytoskeletal organisation in
transiently transfected cells [31]. Eph-ephrin signalling
may also be involved in the demarcation of arterial and
Figure 4
(A) Coomassie stained duplicate gel for loading comparison. (B) Western analysis of EphB4 protein expression in colon
tumour (T) and matched normal mucosa (N) from five different patients. The size markers in kDa are shown on the left. The
arrow indicates the normal EphB4 protein.BMC Molecular Biology 2001, 2:15 http://www.biomedcentral.com/1471-2199/2/15
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venous vessels and the recruitment of endothelial cells to
the formation of new vasculature [8,32]. Adams et al
(2001) have shown that embryos expressing the EphB4
ligand ephrnB2 lacking the cytoplasmic domain have de-
fects in vasculogenesis and angiogenesis and this results in
midgestation lethality similar to ephrinB2 null mutants
[33]. EphrinB2 is a promiscuous ligand that binds to a
number of EphB receptors and may regulate many differ-
ent functions. This may explain why these mutations are
lethal. However these results in combination imply that
Eph receptor signalling may regulate changes in cell-ma-
trix and cell-cell adhesion and cytoskeletal organisation
while ephrin ligand signalling is important for vasculo-
genesis and angiogenesis.
Of particular reference to a proposed function in cancer
development is the demonstration that Eph-ephrin sig-
nalling can prevent the formation of gap junctions be-
tween neighbouring cells, as do the products of various
oncogenes including src, neu, raf, fps and ras [34,35]. The
loss of gap junctional communication correlates with pro-
gression to a malignant phenotype for many cancer cell
types [35].
In the Eph-ephrin signalling system, Stein et al. (1998)
have shown that the density of ephrin plays an important
part in interpreting different signals [36]. Tetramers of
ephrins signal through EphRs to induce cell adhesion in a
heterologous system and in primary cultures but the
dimeric form is ineffective in this function even though
both forms are equally effective in eliciting EphB1 auto-
phosphorylation. If EphB4 is overexpressed in colon tu-
mour cells, ephrins may no longer be able to form
tetramers and may therefore not induce cell adhesion,
which would then assist in the spread of cancer cells.
However, the fact that the dimeric form can also induce
receptor autophosphorylation suggests that this may also
be an important regulatory system in other, as yet un-
known, ways.
Tumour cells need to acquire a vascular network if they are
to grow beyond a few millimetres in diameter. Because
EphB4 has been characterised as a key player in the path-
Figure 5
Immunohistochemical localisation of EphB4 expression in three different colon cancers and matched normal mucosa. The
brown stain from the biotinylated secondary antibody indicates the EphB4 protein. Nuclei are stained with Harris haematoxylin
and appear blue. High power (100X) magnification images of three different adenocarcinomas (well differentiated, moderately
well differentiated and poorly differentiated) and their matched normal mucosa are shown. Strong staining of the tumour tissue
and very weak, diffuse staining of normal tissue was evident for each sample set. There was no cross-reactivity with the sec-
ondary antibody alone (result not shown).BMC Molecular Biology 2001, 2:15 http://www.biomedcentral.com/1471-2199/2/15
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way that distinguishes arteries and veins [8,37], it was pos-
sible that the up-regulation of expression of EphB4 was
actually in stromal cells such as the endothelial cells re-
cruited by the tumour cells for this network. We used im-
munohistochemical techniques and an EphB4-specific
antibody to identify which cells within the tumour tissue
were expressing the EphB4 protein. Our results have
shown that the up-regulation of the EphB4 mRNA corre-
sponds to an increase in the amount of EphB4 protein
produced within the tumour tissue for all six patients an-
alysed and that this expression is a localised in the tumour
epithelial cells with only weak, diffuse staining in the nor-
mal mucosa and stromal cells.
Conclusions
Increased expression of the EphB4 gene suggests that
EphB4 signalling may play an intrinsic role in the devel-
opment of a tumour phenotype in colon cancer and raises
questions concerning this potential role. Further experi-
ments, including targeted disruption of the EphB4 gene in
colon cancer cells and testing the effect of this on the abil-
ity of the tumour cells to grow in vitro and in vivo, may
provide useful information for developing strategies for
treatment of this disease. Furthermore, the identification
of factors that activate the transcription of EphB4 in colon
cancer cells may identify signalling mechanisms that are
specific to tumour cells. The elucidation of these early
events in the signal transduction pathways that lead to de-
velopment or progression of the tumour cell phenotype




Tumour and normal tissue were collected at the time of re-
section from 60 patients (35 male, 25 female), median
age 69 years (range 43–91 years) with colorectal cancer at
The Queen Elizabeth Hospital, Adelaide, Australia, and
snap frozen in liquid nitrogen. All tumour tissue was his-
tologically confirmed as adenocarcinoma, and staged us-
ing the ACPS classification system. Liver metastases
consistent with colorectal primaries were also collected
from five of these patients after hemi-hepatectomy. In-
formed consent was obtained in all cases and ethics ap-
proval was obtained from The Queen Elizabeth Hospital
Ethics Committee.
Cell culture
Colon cancer cell lines SW480, SW620, SW48, LIM1215,
LIM2405, HT29, LIM1863, LIM2412 and LIM2099 were
cultured in HEPES-buffered RPMI 1640 medium (Life
Technologies, Grand Island, N.Y.), pH 7.4. The medium
was supplemented with 100 U/ml penicillin, 100 µg/ml
streptomycin, 160 µg/ml L-glutamine and 10% heat-inac-
tivated foetal bovine serum (JRH Biosciences, Lenexa, KS)
in 75 cm2 vented tissue culture flasks at 37°C in a 5% CO2
environment. Cells were collected at >90% confluency by
trypsin digestion and centrifugation for 5 min at 1000
rpm, resuspended in phosphate buffered saline (PBS) and
counted using a haemocytometer. The LIM cell lines were
kindly provided by Dr R. Whitehead (Ludwig Institute for
Cancer Research, Melbourne, Australia); the remainder
were purchased from the American Type Culture Collec-
tion (ATCC, Rockville, MD).
RNA and protein extraction from tissues and cell lines
RNA and protein were isolated sequentially from tissue
samples and cell lines using Trizol™ solution (Sigma, St.
Louis, MO). Growth medium was aspirated from the flask
of growing cells (>90% confluency) and the cells washed
with phosphate-buffered saline (PBS) before being direct-
ly lysed using 1 ml of the Trizol™ solution. After a five min
incubation with gentle rocking, the cell lysate was re-
moved to a 2 ml eppendorf tube. Tissue samples (0.5 – 1.0
g) were ground in liquid nitrogen using a mortar and pes-
tle, then transferred to an eppendorf tube containing 1 ml
Trizol™ solution. The RNA and protein fractions were ex-
tracted from each of these samples using the manufactur-
er's recommendations. Protein concentrations were
determined using the DC Protein Assay Kit from Biorad
(Sydney, NSW, Australia) following the manufacturer's
protocol and using bovine serum albumin diluted from
0.2 mg/ml to 1.5 mg/ml to determine the standard curve.
cDNA array analysis
Two duplicate (from the same manufacturing batch) Atlas
Cancer cDNA arrays (Clontech, Palo Alto, CA) were differ-
entially screened with cDNA probes made using mRNA
extracted from tumour and matched normal tissue from
two different patients and the supplied control mRNA.
Total RNA (25 µg) was DNase treated (Life Technologies,
Bethesda, MD) then re-extracted using Trizol™ solution.
mRNA was prepared from these samples using the Oligo-
tex mRNA purification kit (Qiagen, Germany) following
the manufacturer's protocol. cDNA probes were synthe-
sised using the method supplied with the cDNA array fil-
ters. These 32P-labelled probes were hybridised to
different arrays in 15 ml ExpressHyb™ solution (Clon-
tech) overnight at 68°C, then washed at high stringency in
the recommended wash solutions. Blots were exposed to
phosphorimager plates overnight, then visualised using a
Fuji-BAS phosphorimager. The blots were re-hybridised
with a new probe after removal of the previous probe by
incubation in boiling 0.1% SDS for 10 min and confirma-
tion by phosphorimaging that there was no residual sig-
nal retained.
Semi-quantitative and Relative RT-PCR
Total RNA (2 µg) was reverse transcribed at 37°C using 3
µl pD(N)6 primers (Life Technologies), 200 µM each de-BMC Molecular Biology 2001, 2:15 http://www.biomedcentral.com/1471-2199/2/15
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oxyribonucleoside triphosphate (dNTP) (Pharmacia,
Uppsala, Sweden) and 200 U MMLV reverse transcriptase
(Life Technologies) in a reaction volume of 30 µl. Primers
specific to either EphB4 (EphB4F1 5'- GAG AGG TAC CTC
CTG CAG TGT C and EphB4R1 5'- CCA TGT CCG ATG
AGA TAC TGT CCG-3' or EphB4 F2 5'-CGG ACA GTA TCT
CAT CGG ACA TG-3' and EphB4 R2 5'-GCT TGG CCT
GGG ACT TCA TGT G-3') or CK19 (CK19 F 5'-GAC TAC
AGC CAC TAC TAC ACG ACC and CK19 R 5'-AGC CGC
GAC TTG ATG TCC ATG AGC C), were used in a PCR re-
action carried out in a Perkin Elmer thermocycler with the
following conditions: 1.5 mM MgCl2, 200 µM each dNTP,
50 ng of each primer, and 0.5 units of Tth polymerase in
1 ×  PCR buffer (10 ×  PCR buffer is 670 mM Tris-HCl pH
8.8, 166 mM [NH4]2SO4, 4.5% Triton X-100, 2 mg/mL
Gelatin) (Biotech International, Perth, Australia). Cycling
conditions included an initial denaturation at 94°C for 5
min, followed by 30 cycles of 94°C for 30 sec, 60°C
(EphB4 set 1) or 63°C (EphB4 set 2) or 68°C (CK19) for
30 sec, and 72°C for 30 sec, with a final extension of 72°C
for 7 min. The QuantumRNA™ 18S Internal Standards kit
from Ambion (Austin, TX) was used to calculate the rela-
tive abundance of transcripts corresponding to EphB4.
One microlitre of a 3:7 ratio of 18S primer to 18S compe-
timer (product of 489 bp) was added to each reaction tube
and the annealing temperature increased to 62°C as rec-
ommended in the Ambion protocol. PCR products were
separated by electrophoresis through 1.5% agarose gels
and the results analysed using the Kodak Digital Science
ID 2.0.2 program (Eastman Kodak Company, New Ha-
ven, CT, USA). The level of EphB4 expression in each sam-
ple was calculated relative to the amount of 18S product
within that sample (expressed as a ratio). The relative ex-
pression of tumour compared to normal was compared
using the GraphPad Instat™ program (http://www.graph-
pad.com/instat3/instat.htm).
Western Analysis
Protein samples (20 µg) extracted from tumour and
matched normal tissue were analyzed in duplicate using
6% SDS-PAGE gels [24]. One of these gels was stained
with coomassie blue to visualise the proteins and com-
pare loading of samples and the second was used for
transfer to Immobilon-P PVDF membrane (Millipore
Corporation, Bedford, MA). EphB4 antigens were detect-
ed using a 1:1000 dilution of the rabbit polyclonal anti-
body EphB4 (H-200) (Santa Cruz Biotechnology, Santa
Cruz, CA) raised to human EphB4. After an overnight in-
cubation at 4°C, the primary antibody was detected using
the Lumi-LightPLUS Western Blotting kit (Roche Biochem-
icals, Mannhein, Germany) following the manufacturer's
recommendation, and between 10s and 30s exposure to
Hyperfilm™ ECL™ (Amersham Pharmacia Biotech, UK).
Immunohistochemistry
Sections (8 µm) of fresh frozen tissue were mounted on
poly-L-lysine coated slides, fixed in acetone, air dried,
then frozen until required at -80°C. Endogenous peroxi-
dase activity was blocked with 0.5% hydrogen peroxide in
methanol for 30 min at room temperature. Nonspecific
binding sites were blocked with 3% normal goat serum in
PBS for 20 min at room temperature and the Vector Labo-
ratories (Burlingame, CA) Avidin/Biotin blocking kit fol-
lowing the manufacturer's instructions. The sections were
then incubated overnight at 4°C with a 1:200 dilution of
the EphB4-specific antibody used for the western analysis.
After rinsing with PBS, the sections were incubated with
biotinylated goat anti-rabbit IgG (Vector Laboratories) for
30 min at room temperature followed by washing with
PBS. Immunoreactivity was detected with the avidin-bi-
otin system (Vector Laboratories) using 18.5 mM 3,3'-di-
aminobenzidine tetrahydrochloride (Sigma) as a
chromogen for 2 min. The sections were then counter-
stained using Harris haematoxylin, dehydrated, cleared
using SUB-X clearing solution (Surgipath Medical Indus-
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